RESEARCH TRIANGLE PARK, NC--(Marketwire - January 6, 2010) - Cutting Edge Information (CEI)
announces the release of its newest diabetes market forecast study.
(
http://www.cuttingedgeinfo.com/diabetes-forecast/)
Since 2008, Cutting Edge Information has developed forecasting data for the
diabetes treatment market. The new report -- "Diabetes Market Forecast to
2015" -- provides a deep analysis of the relevant clinical, commercial, and
market trends affecting diabetes therapeutics today and their impact
leading into the next decade. In addition to detailed drug, class, and
company profiles, the study includes primary research findings generated
from survey data and interviews with leading physicians and marketing
executives.
The study also details the historical, current and forecasted performance
of 45 drugs treating Type 1 and Type 2 diabetes and their associated
complications. Included are marketed brands and pipeline products in
clinical development and analysis of the top 10 drug makers in the diabetes
area. The report's structure leads to data comparisons and analysis across
multiple levels.
A complimentary report brochure is available for download at
http://www.cuttingedgeinfo.com/diabetes-forecast/?download/
The report's expanded content uncovers physician and industry perspectives
on the current direction of diabetes research, most effective marketed
therapies -- as well as novel treatments in development -- and unmet needs
across various regions in the global diabetes market. Special attention is
given to companies' responses to the FDA's new cardiovascular guidelines.
"The diabetes market is expected to see incredible growth in the near
future, at about 70 percent by 2015," said Shaylyn Pike, lead author of the
report. "Our study points out key areas of opportunity for pharma
companies, as well as research areas to avoid -- information especially
helpful as me-too drugs continue to fall out of favor."
The report is organized into profiles for individual brands and drug
manufacturers.
Brand Profiles detail a product's competitive and strategic positioning,
market opportunities, and patent and litigation data. Profiles include the
following information:
-- Drug's current and projected competitive strength
-- Current/projected sales position within its class
-- Sales projection charts through 2015
-- Assessment of competition
-- Materiality charts
-- Clinical trial information
-- Patent expirations
Company Profiles show breakdowns for 10 companies that have established
antidiabetes franchises or exciting development pipelines. Profiles
contain:
-- Diabetes market position/ranking
-- Market forecast
-- Strengths analysis
-- Growth areas analysis
-- Market-changing opportunities analysis
-- Key products breakdown
Contact Information: CONTACT INFORMATION:
Stephanie Swanson
919-433-0212